Suppr超能文献

阿片类药物过量预防及纳洛酮急救包:我们所知道的与我们所不知道的

Opioid overdose prevention and naloxone rescue kits: what we know and what we don't know.

作者信息

Kerensky Todd, Walley Alexander Y

机构信息

Instructor of Medicine, Boston University School of Medicine, Boston Medical Center, 801 Massachusetts Avenue, Floor 2, Boston, MA, 02118, USA.

Section of General Internal Medicine, Clinical Addiction Research and Education Unit, Boston University School of Medicine, Boston Medical Center, 801 Massachusetts Avenue, Floor 2, Boston, MA, 02118, USA.

出版信息

Addict Sci Clin Pract. 2017 Jan 7;12(1):4. doi: 10.1186/s13722-016-0068-3.

Abstract

The opioid use and overdose crisis is persistent and dynamic. Opioid overdoses were initially driven in the 1990s and 2000s by the increasing availability and misuse of prescription opioids. More recently, opioid overdoses are increasing at alarming rates due to wider use of heroin, which in some places is mixed with fentanyl or fentanyl derivatives. Naloxone access for opioid overdose rescue is one of the US Department of Health and Human Services' three priority areas for responding to the opioid crisis. This article summarizes the known benefits of naloxone access and details unanswered questions about overdose education and naloxone rescue kits. Hopefully future research will address these knowledge gaps, improve the effectiveness of opioid overdose education and naloxone distribution programs, and unlock the full promise of naloxone rescue kits.

摘要

阿片类药物的使用和过量危机持续且动态变化。在20世纪90年代和21世纪初,阿片类药物过量最初是由处方阿片类药物供应增加和滥用所驱动。最近,由于海洛因的广泛使用,阿片类药物过量正以惊人的速度增加,在一些地方,海洛因与芬太尼或芬太尼衍生物混合在一起。获取纳洛酮用于阿片类药物过量急救是美国卫生与公众服务部应对阿片类药物危机的三个优先领域之一。本文总结了获取纳洛酮的已知益处,并详细阐述了关于过量用药教育和纳洛酮急救包的未解决问题。希望未来的研究能够填补这些知识空白,提高阿片类药物过量教育和纳洛酮分发项目的有效性,并充分发挥纳洛酮急救包的潜力。

相似文献

1
Opioid overdose prevention and naloxone rescue kits: what we know and what we don't know.
Addict Sci Clin Pract. 2017 Jan 7;12(1):4. doi: 10.1186/s13722-016-0068-3.
2
Opioid education and nasal naloxone rescue kits in the emergency department.
West J Emerg Med. 2015 May;16(3):381-4. doi: 10.5811/westjem.2015.2.24909. Epub 2015 Apr 1.
3
Awareness and Attitudes Toward Intranasal Naloxone Rescue for Opioid Overdose Prevention.
J Subst Abuse Treat. 2016 Oct;69:44-9. doi: 10.1016/j.jsat.2016.07.005. Epub 2016 Jul 18.
6
Do heroin overdose patients require observation after receiving naloxone?
Clin Toxicol (Phila). 2017 Feb;55(2):81-87. doi: 10.1080/15563650.2016.1253846. Epub 2016 Nov 16.
9
Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study.
Lancet Public Health. 2022 Mar;7(3):e210-e218. doi: 10.1016/S2468-2667(21)00304-2. Epub 2022 Feb 10.
10
Overdose education and naloxone distribution for veterans with opioid use disorder: Results from a pilot initiative.
J Addict Dis. 2017 Oct-Dec;36(4):217-221. doi: 10.1080/10550887.2017.1333331. Epub 2017 May 26.

引用本文的文献

2
Price Sensitivity and Information Barriers to the Take-Up of Naloxone.
Am Econ J Econ Policy. 2024 Nov;16(4):463-490. doi: 10.1257/pol.20230135.
5
Intranasal overdose reversal formulations: a rapid review of available agents.
Pain Manag. 2025 Feb;15(2):105-113. doi: 10.1080/17581869.2025.2461445. Epub 2025 Feb 4.
6
Oxytocin Reduces Noradrenergic-Induced Opioid-Like Withdrawal Symptoms in Individuals on Opioid Agonist Therapy.
Biol Psychiatry Glob Open Sci. 2024 Sep 18;5(1):100395. doi: 10.1016/j.bpsgos.2024.100395. eCollection 2025 Jan.
7
Take-home naloxone in multicentre emergency settings: the TIME feasibility cluster RCT.
Health Technol Assess. 2024 Oct;28(74):1-69. doi: 10.3310/YNRC8249.
8
Scaling up! Staff e-learning for a national take-home naloxone program.
Front Digit Health. 2024 Sep 17;6:1404646. doi: 10.3389/fdgth.2024.1404646. eCollection 2024.
9
High-dose naloxone formulations are not as essential as we thought.
Harm Reduct J. 2024 May 13;21(1):93. doi: 10.1186/s12954-024-00994-z.
10
Retrospective study investigating naloxone prescribing and cost in US Medicaid and Medicare patients.
BMJ Open. 2024 May 1;14(5):e078592. doi: 10.1136/bmjopen-2023-078592.

本文引用的文献

1
Increases in Fentanyl-Related Overdose Deaths - Florida and Ohio, 2013-2015.
MMWR Morb Mortal Wkly Rep. 2016 Aug 26;65(33):844-9. doi: 10.15585/mmwr.mm6533a3.
2
Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths - 27 States, 2013-2014.
MMWR Morb Mortal Wkly Rep. 2016 Aug 26;65(33):837-43. doi: 10.15585/mmwr.mm6533a2.
5
Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria.
Addiction. 2016 Jul;111(7):1177-87. doi: 10.1111/add.13326. Epub 2016 Mar 30.
6
CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016.
MMWR Recomm Rep. 2016 Mar 18;65(1):1-49. doi: 10.15585/mmwr.rr6501e1.
7
Increase in Naloxone Prescriptions Dispensed in US Retail Pharmacies Since 2013.
Am J Public Health. 2016 Apr;106(4):689-90. doi: 10.2105/AJPH.2016.303062. Epub 2016 Feb 18.
8
Relationship between Nonmedical Prescription-Opioid Use and Heroin Use.
N Engl J Med. 2016 Jan 14;374(2):154-63. doi: 10.1056/NEJMra1508490.
9
Increases in Drug and Opioid Overdose Deaths--United States, 2000-2014.
MMWR Morb Mortal Wkly Rep. 2016 Jan 1;64(50-51):1378-82. doi: 10.15585/mmwr.mm6450a3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验